{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 9 Day 1 (n=170, 161)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 10 Day 1 (n=165, 164)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 11 Day 1 (n=158, 158)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 12 Day 1 (n=151, 146)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 13 Day 1 (n=149, 143)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 14 Day 1 (n=152, 143)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 15 Day 1 (n=149, 140)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 16 Day 1 (n=142, 141)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 17 Day 1 (n=145, 142)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 18 Day 1 (n=141, 140)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 19 Day 1 (n=140, 138)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 20 Day 1 (n=139, 134)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"Depletion is defined as a CD19 value \\<80 cells/mm\\^3.","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"NUMBER","populationDescription":"ITT Population. Here, number of participants analyzed = participants evaluable for the outcome measure. Here \"n\" = number of participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Stage I and II (maintenance): D1 of Cy 9 to 20 (1 Cy=8 weeks) (up to data cutoff of 11 Jan 2016 [up to 6 years])","title":"Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase","type":"SECONDARY","unitOfMeasure":"percentage of participants"}